Daebong LS Reports Decrease in Q1 Sales... "Expecting Record High This Year Due to Recovery in Cosmetics Demand"

[Asia Economy Reporter Hyunseok Yoo] Daebong LS announced on the 17th that it recorded consolidated sales of 18.6 billion KRW, operating profit of 2.1 billion KRW, and net profit of 2.3 billion KRW in the first quarter. Sales and operating profit decreased by 9.6% and 25.2% respectively compared to the same period last year, but net profit slightly increased by 5.1%.

PNK Skin Clinical Center, a subsidiary listed on KOSDAQ last September, expects continued growth in research orders due to the expansion of new research facilities and the recovery of global cosmetic consumption demand, reflecting favorable conditions in the upstream industry. In particular, this year's performance is expected to surpass last year's results. Last year, it achieved consolidated sales of 76.2 billion KRW and operating profit of 8.1 billion KRW.

A company official stated, “In the same period last year, sales performance was driven by disinfectant and antibacterial raw materials due to COVID-19, but this year, operating profit decreased due to a decline in sales of those raw materials. We will do our best to secure sustainable growth momentum and repay all stakeholders by achieving good results through independent development of functional cosmetic materials, overseas market expansion strategies, development of oral modified new drugs, and promotion of technology exports for new synthetic methods.”

Daebong LS aims for a quantum leap by leading the clean beauty and green bio sectors through the completion of state-of-the-art smart production facilities and an R&D center on a 9,633.4㎡ site (210-5, Songdo-dong) within the Songdo Advanced Industrial Cluster by the end of 2022.

This content was produced with the assistance of AI translation services.